Fast antimicrobial susceptibility test (AST) results from the Accelerate Pheno system help clinicians improve bed management and outcomes for patients with bacteremia, a leading cause of sepsis. And the sooner patients are discharged or stepped down, the sooner their beds are free for other patients—especially crucial during a crisis like the COVID-19 pandemic.
Multiple clinical studies have found that using the Accelerate Pheno system can help:
- Cut time to optimal therapy (TTOT) by 24 hours or more
- Shorten duration of antibiotic therapy by up to 4 days
- Reduce length of stay by 2 days or more
The examples below show length of stay reductions at three U.S. hospitals, and how that translates into savings in bed days to support bed turnover. Use the form to the right to get our Fact Sheet showing the benefits—including reductions in length of stay, readmissions, and antibiotic use—experienced at five hospitals.
How 5 hospitals improved outcomes and quality while reducing cost
Complete the form below to download yours.
Length of Stay Reductions
Bed-Day Savings at UAMS (derived from study data3)
456 patients/yr x 1.8 days reduced LOS = 821 bed days/yr saved
Fast Results for Clinical Optimization
Clinical microbiology laboratories at hospitals across the United States are using the Accelerate Pheno system to cut the wait time for antimicrobial susceptibility test (AST) results by approximately 40 hours. Antimicrobial stewardship teams are using these expedited phenotypic AST results to support faster and better decision-making around antibiotic therapy recommendations.
Earlier clinical optimization with faster antimicrobial susceptibility results from the Accelerate Pheno system provides multiple benefits in addition to LOS reductions:
- ID in ~2 hours, AST in ~7 hours
- Expedited results reporting4
- Timely therapy optimization2,5,6 (escalation and de-escalation)
- Reduced antibiotic days on therapy1,2,3
References
1Sheth S, et al. Impact of Rapid Identification (ID) and Antimicrobial Susceptibility Testing (AST) on Antibiotic Therapy and Outcomes for Patients with Bacteraemia/Candidaemia. Poster presented at: ECCMID; April 2019, Amsterdam, Netherlands.
2Walsh T. Impact of Accelerate Pheno™ System on Management of Gram Negative Bacteremia at an Academic Medical Center. Poster presented at: SCACM WV; October 2019, Morgantown, WV.
3Dare RK, et al. Clinical Impact of Accelerate Pheno™ Rapid Blood Culture Detection System in Bacteremic Patients. Clinical Infectious Diseases 2020, ciaa649, https://doi.org/10.1093/cid/ciaa649 [Epub ahead of print].
4Charnot-Katsikas A, et al. Use of the Accelerate Pheno™ System for Identification and Antimicrobial Susceptibility Testing of Pathogens in Positive Blood Cultures and Impact on Time to Results and Workflow. J Clin Microbiol 2018; 56:e01166-17.
5Banerjee R, et al. Randomized clinical trial evaluating clinical impact of RAPid IDentification and antimicrobial Susceptibility testing for Gram-Negative bacteremia (RAPIDS-GN). Poster presented at: IDWeek™; October 2019, Washington, D.C.
6Schneider JC, et al. Susceptibility Provision Enhances Effective De-Escalation (SPEED). Utilizing Rapid Phenotypic Susceptibility Testing in Gram-Negative Bloodstream Infections and its Potential Clinical Impact. J Antimicrob Chemother 2019; 74 Suppl 1: i16–i23.
Ready for fast susceptibility testing? Request a consultation